Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43298 | 1.00 | ALDH1A1 (0.49) | ALDH1A1SLC6A4MAPTCYP1A2CYP3A4 | |
| SCHEMBL895913 | 1.00 | ALDH1A1 (0.49) | ALDH1A1SLC6A4MAPTCYP1A2CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL4821086 | 0.84 | ALDH1A1 (0.45) | ALDH1A1SLC6A4MAPTCYP1A2CYP3A4 | |
| SCHEMBL18833848 | 0.82 | LOXL2 (0.53) | ALDH1A1MAPTCYP1A2CYP3A4TSHR | |
| SCHEMBL942066 | 0.82 | LOXL2 (0.53) | ALDH1A1MAPTCYP1A2CYP3A4TSHR | |
| SCHEMBL16805961 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MAPTCYP1A2CYP3A4TSHR | |
| SCHEMBL6690598 | 0.81 | LOXL2 (0.52) | ALDH1A1MAPTCYP1A2CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL11740245 | 0.81 | LOXL2 (0.52) | ALDH1A1MAPTCYP1A2CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL1820970 | 0.81 | LOXL2 (0.52) | ALDH1A1MAPTCYP1A2CYP3A4TSHR | |
| SCHEMBL5201413 | 0.81 | ALDH1A1 (0.53) | ALDH1A1MAPTCYP3A4TSHRLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160177354-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | SAFC, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-2462115-B1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140371456-A1 | Enzymatic Transamination of Cyclopamine Analogs | ROYALTY SECURITY, LLC | 2014-12-18 | — | — | US | disclosed |
| US-8703448-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| CN-102574791-A | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS INC | 2012-07-11 | — | — | CN | disclosed |
| EP-2462115-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | Infinity Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| WO-2011017551-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | ALDH1A1 693/4885SLC6A4 1280/4885MAPT 2225/4885 |
| US-20140371456-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | ALDH1A1 693/4885SLC6A4 1280/4885MAPT 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.